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Abstract
Background
Serological follow-up of acute Q-fever patients is important for detection of chronic infection
but there is no consensus on its frequency and duration. The 2007–2009 Q-fever epidemic
in the Netherlands allowed for long-term follow-up of a large cohort of acute Q-fever
patients. The aim of this study was to validate the current follow-up strategy targeted to iden-
tify patients with chronic Q-fever.
Methods
A cohort of adult acute Q-fever patients, diagnosed between 2007 and 2009, for whom a
twelve-month follow-up sample was available, was invited to complete a questionnaire and
provide a blood sample, four years after the acute episode. Antibody profiles, determined
by immunofluorescence assay in serum, were investigated with a special focus on high
titres of IgG antibodies against phase I of Coxiella burnetii, as these are considered indica-
tive for possible chronic Q-fever.
Results
Of the invited 1,907 patients fulfilling inclusion criteria, 1,289 (67.6%) were included in the
analysis. At any time during the four-year follow-up period, 58 (4.5%) patients were classi-
fied as possible, probable, or proven chronic Q-fever according to the Dutch Q-fever Con-
sensus Group criteria (which uses IgG phase I1:1,024 to as serologic criterion for chronic
Q-fever). Fifty-two (89.7%) of these were identified within the first year after the acute epi-
sode. Of the six patients that were detected for the first time at four-year follow-up, five had
an IgG phase I titre of 1:512 at twelve months.
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Conclusions
A twelve-month follow-up check after acute Q-fever is recommended as it adequately
detects chronic Q-fever in patients without known risk factors. Additional serological and
clinical follow-up is recommended for patients with IgG phase I1:512, as they showed the
highest risk to progress to chronic Q-fever.
Introduction
Q-fever is a bacterial zoonosis caused by Coxiella burnetii. Between 2007 and 2009, one of the
largest documented Q-fever epidemics occurred in the Netherlands, which originated from
dairy goat farms and caused over 3,500 notified cases [1].
After an episode of acute Q-fever, C. burnetiimay persist intracellularly, causing progres-
sion to chronic infection. While acute Q-fever presents as febrile illness, pneumonia or
hepatitis, chronic Q-fever mainly presents as endocarditis or vascular infections with a high
morbidity and mortality [2]. Patients with resolving acute Q-fever reach peak antibody titres in
the first months after infection [3, 4], in contrast to chronic Q-fever patients, who have persis-
tent elevated antibody titres, specifically IgG phase I [5].
In the aftermath of the Dutch Q-fever epidemic, the focus shifted from diagnosing acute Q-
fever patients to early identification and treatment of patients with chronic Q-fever [2]. Based
on the literature, 0–5% of acute Q-fever patients are estimated to develop chronic Q-fever [6].
These figures lack accuracy as case definitions differ for both acute and chronic infections [6].
There is also considerable uncertainty about the time it takes to develop chronic Q-fever which
ranges from months to years [7–9]. A contributing cause of this variation is the diagnostic
delay, as it is difficult to diagnose chronic Q-fever.
Nonetheless, follow-up to detect chronicity after acute Q-fever is generally considered
essential, but there is no consensus about optimal timing, frequency, duration and the cut-off
level of antibody titres [6, 9–12].
To identify chronic Q-fever patients as early as possible, the Jeroen Bosch Hospital (JBH) in
‘s-Hertogenbosch, located in the centre of the Dutch epidemic, provided active serological fol-
low-up to acute Q-fever patients at three, six, and twelve months after diagnosis [10, 13]. A four-
year follow-up study was conducted (Q-HORT) to validate the routine follow-up strategy for
detecting chronic Q-fever by comparing the serological results in the first year with those at
four-year follow-up. The aim of this study was to: (1) validate this follow-up strategy targeted to
identify patients with chronic Q-fever; (2) check whether there are any groups of patients that
need follow-up later than twelve months because of the risk to progress to chronic Q-fever; and
(3) identify factors associated with an increased IgG phase I titre at four-year follow-up.
Methods
Ethics statement
This study was approved by the Medical Ethical Committee Brabant (METC Brabant, refer-
ence NL35654.028.11) and the Internal Review Board of JBH. Written informed consent was
obtained from all participants.
Study population
All patients diagnosed with acute Q-fever in 2007, 2008, and 2009 at the Laboratory of Medical
Microbiology of JBH (catchment area of approximately 550,000 persons) were contacted for
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follow-up four years after their initial diagnosis. One-year follow-up results for the 2007 and
2008 cohort are described by van der Hoek et al. [10].
Acute Q-fever case definition
Suspected Q-fever patients were referred by a general practitioner (GP) or a hospital physician
for laboratory confirmation of the presumptive diagnosis of acute Q-fever. Diagnostic blood
samples and samples at three and six months were used for identification of acute cases and
confirmation of the diagnosis. A laboratory-confirmed acute Q-fever case was defined as either
one of the following three criteria: (1) both IgM and IgG phase II antibody titres1:32 in the
diagnostic sample by immunofluorescence assay (IFA; Focus Diagnostics, Inc., Cypress, CA,
USA) with IgG phase II1:64 during follow-up; (2) enzyme-linked immunosorbent assay
(ELISA; Virion\Serion, Würzburg, Germany) IgM phase II positive and IFA IgG phase II
1:32 at diagnosis with IgG phase II1:64 during follow-up; (3) a positive polymerase chain
reaction (PCR; in-house assay [14]) result preceding seroconversion in IFA (Focus Diagnostics,
Inc.) with IgG phase II1:64 during follow-up.
Laboratory methods
ELISA IgM phase II and IFA IgM and IgG phase I and II were performed on diagnostic sam-
ples following the manufacturer’s instructions. IFA titres of1:32 were considered positive.
An in-house PCR test was performed when the sample was taken14 days after onset of ill-
ness. The details of the PCR in-house assay targeting the IS1111 insertion element have been
described elsewhere [14]. IFA IgG phase I and II tests were performed in all three-, six-, and
twelve month follow-up samples using two-fold dilutions starting at 1:32. An additional PCR
test was performed when there was suspicion of chronic Q-fever. Diagnostic evaluations for
patients suspected of having acute Q-fever were performed according to the diagnostic algo-
rithm that was established in our laboratory in 2009 [15].
Data collection
Serological data at diagnosis and at three-, six-, and twelve-month follow-up were available
from the laboratory information system. Four years after diagnosis, a study information pack
was sent by post which contained: an invitation for participation in this study, a questionnaire,
an informed consent form, a diagnostic request form and leaflets showing laboratory locations.
Patients were asked to visit a laboratory facility in their neighbourhood to have a blood sample
taken. The signed informed consent form and questionnaire were to be returned by post.
Patients who did not respond within four weeks were sent all of the study materials a second
time.
The questionnaire consisted of questions on general demographics and risk factors for
chronic Q-fever. Participants who failed to complete all of the questions in the questionnaire
were subsequently contacted (by email, phone, or post). Answers were entered into IBM SPSS
Statistics for Windows version 19.0.0 (SPSS Inc., Armonk, NY, USA) and 5% of the question-
naires were double-checked.
When participants reported that they had consulted a physician for cardiovascular prob-
lems, the hospital information systems of the two hospitals in the catchment area were checked
for specific information on the condition (with the consent of the participants). The individual
prescription and use of antibiotics was not available for most of the patients.
The blood samples were used to determine IgM and IgG phase I and II in serum using IFA.
PCR was performed when IgG phase I was1:512. Both participants and their GPs received
the laboratory results.
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Chronic Q-fever case definition
Participants with IgG phase I1:1,024 were categorized as proven, probable, or possible
chronic Q-fever patients according to the Dutch Q-fever Consensus Group criteria [16].
Proven chronic Q-fever is defined as positive C. burnetii PCR (or culture) in blood or tissue (in
the absence of acute infection), or a high IgG phase I titre (1:1,024 for commercial IFA) in
combination with confirmed endocarditis according to the revised Duke criteria [17], or evi-
dent infection of aneurysm or vascular graft by imaging techniques. Probable chronic Q-fever
patients have an IgG phase I1:1,024, in combination with risk factors for chronic Q-fever,
echocardiographic abnormalities that do not meet the revised Duke criteria [17], rare manifes-
tations of Q-fever or signs of systemic inflammation. Possible chronic Q-fever cases have an
IgG phase I1:1,024, and do not have any of the manifestations mentioned in the categories of
proven and probable Q-fever.
At the twelve-month follow-up of this cohort, these criteria were not yet established and an
IgG phase I1:2,048 was used to diagnose chronic Q-fever and to refer patients for clinical
evaluation.
Exclusion criteria
Patients without a serum sample obtained twelve months after diagnosis and those younger
than 18 years at the four-year follow-up were excluded from this study. Patients were excluded
for analysis when: (i) the date of onset of symptoms was uncertain; (ii) proven chronic Q-fever
or a probable chronic infection was identified in the first blood sample that was submitted to
the laboratory (i.e., no sample available or taken for an acute C. burnetii infection); (iii) at least
IgM and/or IgG phase I/II antibodies were detected in the first serum sample or the PCR result
was positive, but the IgG phase II titre was1:32 in all follow-up samples (i.e., thus not meet-
ing IgG phase II1:64 during follow-up which is part of the case definition for a laboratory-
confirmed case).
Statistical analysis
For descriptive characteristics, relative frequencies were calculated with median and interquar-
tile ranges (IQRs). Chi-square tests and Mann-Whitney U tests were used to test for differences
between participants and non-responders. A p-value<0.05 was considered as statistically sig-
nificant. The Wilcoxon signed rank test was used to test for differences between the twelve-
month and four-year follow-up samples.
Demographic information and medical conditions present during the four-year follow-up
study were used in a univariable and multivariable logistic regression analysis to find factors
associated with an IgG phase I1:512 at four-year follow-up (index: IgG phase I1:512, refer-
ence: IgG phase I<1:512). For this analysis, heart valve abnormalities were defined as a pros-
thetic valve, grade2 valve stenosis or regurgitation, mitral valve prolapse, bicuspid valve or
other congenital cardiopathies, remodelling or thickening of the valve [18, 19]. Results are
expressed as an odds ratio (OR) with a 95% confidence interval (95% CI). Risk factors which
had a p-value<0.20 at the univariable level were selected for a conditional backward step-wise
multivariable model. The significance level was set to 0.05 for the latter model. To assess the
goodness-of-fit of the final model, a receiver operating characteristic (ROC) curve was pro-
duced and the area under the curve (AUC) was estimated.
Univariable and multivariable analyses were also performed with IgG phase I1:256 and
1:1,024 used as cut-off titres. The analyses were repeated using a proportional odds ratio
model, which enables logistic regression to be generalized to ordinal outcomes (titres), as it
uses the whole spectrum of observations [20]. The proportional odds assumption is that the
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odds of being above any cut-off is the same for all cut-offs, so a single OR is calculated. This
analysis has a greater power than binary logistic regression when ordinal data are dichoto-
mized, and may identify risk factors that would remain undetected in binary logistic regression
[20]. Analyses were performed using IBM SPSS Statistics and R version 3.0.1 (The R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
Inclusion and response
From 2007 to 2009, 2,347 Q-fever diagnoses were made at the Laboratory of Medical Microbi-
ology of the JBH, of whom 1,937 (82.5%) fulfilled the study inclusion criteria, and 1,907
(81.3%) were invited (Fig 1 and Table 1). A complete questionnaire and blood sample were
obtained from 1,341 patients. A total of 52 patients were additionally excluded for analysis
(Fig 1), and 1,289 participants remained, 703 (54.5%) males, with a median age at diagnosis of
51 years (IQR 41−59).
A total of 330 (17.9%) patients did not respond to our invitations to participate in the study.
Just 150 (7.9%) stated that they did not want to participate, and 10 had died between the
twelve-month and four-year follow-up, a fact that was not known to the investigators at the
time of sending the invitations. Characteristics of patients who were included in the analysis
(n = 1,289) were compared to those who were excluded (meaning those who fulfilled the exclu-
sion criteria, who did not participate, or who participated only partially (n = 648; 1,937 partici-
pants fulfilling inclusion criteria minus 1,289 participants included in the analysis)). Excluded
patients were statistically significantly more often male and younger at diagnosis than partici-
pants who were included for analysis (male: 62.2% vs. 54.5%, p = 0.001; median age: 45 vs. 51
years, p<0.001), but antibody levels at diagnosis, three-, six, and twelve-month follow-up, the
geographic location (postal code), and hospitalization for acute Q-fever were not significantly
different between these two groups.
Chronic Q-fever detected during four-year follow-up
At any time during the four-year follow-up period, 58 (4.5%) patients could be classified as
possible, probable, or proven chronic Q-fever (Table 2). The majority of these (52 or 89.7%)
had already been identified within the first year after the acute episode when applying the
Dutch Q-fever Consensus Group criteria [16]. Of the six patients that were detected at four-
year follow-up, five had an IgG phase I of 1:512 at twelve months (5 of a total of 73 individuals
with IgG phase I of 1:512 at month twelve), while one patient had a titre of 1:128 at twelve
months. These six patients were classified as one proven, one probable, and four possible,
chronic Q-fever patients (Table 3). The probable chronic Q-fever patient detected at four-year
follow-up did not have fever, pneumonia, or hepatitis at the time of the primary C. burnetii
infection. Furthermore, three of the 52 patients identified within the first year showed progres-
sion to probable or proven chronic Q-fever at the four-year follow-up (Table 2). Fifteen
patients were identified at any time during the four-year follow-up period with a probable or
proven chronic Q-fever (1.2% of all participants).
Antibodies at four-year follow-up
Median IgG phase I and II antibody titres showed a statistically significant decline from month
twelve to year four (p<0.001 for both IgG phase I and II; Fig 2), i.e. the median IgG phase I and
II titres at four years (box 2 and 4, respectively) are lower than those at month twelve (box 1
and 3, respectively). Since IgG phase I1:1,024 is used as a cut-off for chronic infection, it can
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be seen that some of the chronic Q-fever patients at month twelve (11 out of 52) and all chronic
patients at year four are shown as outliers.
At four-year follow-up, IgG phase II had the highest titres and was detected in almost all
participants (Fig 3). IgM phase II was also still detectable in the majority of participants. Only
14 participants (1.1%) had no detectable antibody levels at four years. An increase in IgG phase
I of two or more dilutions at four-year follow-up was found in 45 (3.5%) patients, of whom 10
had IgG phase I1:64 at month twelve (S1 Table).
Fig 1. Flow chart of the four-year follow-up study (Q-HORT).
doi:10.1371/journal.pone.0131848.g001
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Risk factor analysis
In univariable analysis, age>55 years, aneurysm, vascular prosthesis, heart valve insufficiency
or prosthesis, percutaneous coronary intervention (PCI), coronary stent, rheumatoid arthritis
(RA), and immunosuppressive medication were significantly associated with an IgG phase I
1:512 at four-year follow-up (p<0.05) (Table 4). In multivariable analysis, age>55 years,
aneurysm, PCI, and RA remained significantly associated with an IgG phase I1:512 at four-
year follow-up (AUC 0.68, 95% CI: 0.60−0.76). Known cardiovascular risk factors for chronic
Q-fever (heart valve defect or prosthesis, vascular prosthesis, or aneurysm), when combined,
showed increased odds for an IgG phase I1:512 at four-year follow-up (OR 4.64, 95% CI:
1.86−11.58). The proportional odds ratio analysis resulted in lower risk estimates with nar-
rower 95% confidence intervals, but did not reveal any risk factors that were unidentified in
binary logistic regression.
Table 1. Response at four-year follow-up: received questionnaires and blood samples for each year of diagnosis and total numbers.
Year of diagnosis (year of
invitation)
Fulﬁlled inclusion
criteria
Invited Blood
sample
Questionnaire Blood sample and
questionnaire
n n n (%)a n (%)a n (%)a
2007 (2011) 68 66 (97.1) 50 (75.8) 50 (75.8) 50 (75.8)
2008 (2012) 673 664 (98.7) 470 (70.8) 488 (73.5) 466 (70.2)
2009 (2013) 1,196 1,177
(98.4)
843 (71.6) 860 (73.1) 828 (70.3)
Total 1,937 1,907
(98.5)
1,363 (71.5) 1,398 (73.3) 1,344 (70.5)b
a Percentages calculated with number of invited as denominator.
b Including three questionnaires with the majority of answers missing (Fig 1).
doi:10.1371/journal.pone.0131848.t001
Table 2. Chronic Q-fever patients detected at any time during the four-year follow-up period according to the Dutch Q-fever Consensus Group
classification [16] based on IgG phase I1:1,024 (n = 58).
Chronic Q-fever Proven Probable Possible Total
n n n n
Identiﬁed within the ﬁrst yeara 4 7 41 52
Identiﬁed at four-year follow-upb 1 1c 4 6
Progression detected at four-year follow-upd 2e 1f NAg NA
a The Dutch Q-fever Consensus Group classiﬁcation [16] was not established yet at twelve-month follow-up, and IgG phase I 1:2,048 was used at that
time to diagnose chronic Q-fever. For this table, we applied the criteria of the Dutch Q-fever Consensus Group (IgG phase I 1:1,024) to the data.
b These participants did not meet the criteria of the Dutch Q-fever Consensus Group [16] at twelve months: one possible chronic Q-fever patient had an
IgG phase I titre of 1:128 at month twelve, the remaining ﬁve had a titre of 1:512 (Table 3).
c This patient did not have fever, pneumonia, or hepatitis at time of the primary C. burnetii infection.
d These patients are included in the number of chronic Q-fever cases identiﬁed within the ﬁrst year.
e One possible to proven (at time of visiting the outpatient clinic for our study the newly obtained serum sample was C. burnetii PCR positive), and one
probable to proven (despite serological and clinical follow-up later than twelve months after diagnosis, the probable chronic infection progressed to a
proven Q-fever endocarditis that was detected based on our follow-up study).
f One possible to probable (valvulopathy not meeting the modiﬁed Duke criteria [17]).
g Two possible chronic Q-fever patients (identiﬁed at month twelve) were referred to the outpatient clinic at four-year follow-up, but no progression
occurred.
doi:10.1371/journal.pone.0131848.t002
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Discussion
The most important finding of this four-year follow-up study is that only one possible chronic
Q-fever patient was detected who was not already identified as being at risk at twelve-month
follow-up. This patient had no clinical risk factors and the IgG phase I was only 1:128 at
twelve-month follow-up. Another five patients with newly detected chronic Q-fever at four-
year follow-up had an IgG phase I of 1:512 at twelve months. When combined with the 52
chronic Q-fever patients that had already been detected within the first year, this means that
determination of IgG phase I antibody titre at twelve months with a 1:512 cut-off for further
clinical investigation, detects 98% of people at risk for developing chronic Q-fever (IgG phase
I1:1,024 [16]).
Several guidelines exist on the follow-up of acute and chronic Q-fever patients. The Centres
for Disease Control and Prevention (CDC) published guidelines for both acute and chronic Q-
fever [11], the Dutch Q-fever Consensus Group focussed on chronic Q-fever [16], and also
Table 3. Clinical and serological findings of the six patients identified at four-year follow-up.
No. IgG phase I twelve months IgG phase I four years PCR result Clinical ﬁndings Chronic Q-fever category
1 1:512 1:8,192 Negative Immunosuppression and endocarditisa Proven
2b 1:512 1:4,096 Negative Aneurysm Probable
3 1:512 1:1,024 Negative No risk factorsc Possible
4 1:512 1:1,024 Negative No risk factorsc Possible
5 1:512 1:1,024 Negative No risk factorsc Possible
6 1:128 1:1,024 Negative No risk factorsc Possible
a Unknown whether risk factor (heart valve disease) was present in advance.
b This patient did not have fever, pneumonia, or hepatitis at time of the primary C. burnetii infection.
c No cardiac or vascular risk factors.
doi:10.1371/journal.pone.0131848.t003
Fig 2. Boxplot of IgG phase I and II antibodies at twelve months and four years after acute Q-fever
diagnosis (n = 1,289). The horizontal dark lines within the boxes represent the median antibody titre, the
lower and upper boundaries of the boxes represent the 25th and 75th percentiles, and the T-bars represent
the 2.5th and 97.5th percentiles. Outliers are indicated with dots, extreme outliers (more than three times the
height of the box) with asterisks. Because there is less variation in the IgG phase I titres at four years
compared to the other three boxes shown, this is the only one of the four boxes that shows extreme outliers.
doi:10.1371/journal.pone.0131848.g002
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individual reports gave advice on follow-up [9, 10, 12]. Our follow-up advice deviates at some
points from these published guidelines and recommendations. First, serological follow-up after
three months is, in our opinion, too soon for acute Q-fever patients without known risk factors,
as IgG titres can still increase [4, 10]. Previous studies have been inconclusive in this respect [4,
9, 10, 12]. Secondly, for the majority of patients with IgG phase I1:1,024 at six months we
observed a decline in IgG phase I titres at twelve months (data not shown). This implies that
when serological follow-up is performed at six months, and clinical evaluation is needed for
patients with increased IgG phase I titres [11], a large number of patients would undergo these
clinical evaluations unnecessarily.
Therefore, based on our data, we propose serological follow-up after twelve months in
patients who do not have risk factors (Fig 4). Finally, in the absence of risk factors, patients
with IgG phase I1:512 at twelve-month follow-up, including all possible chronic Q-fever
patients (IgG phase I1:1,024 without any clinical sign of chronic Q-fever), can be considered
to have a low risk of developing proven chronic Q-fever within four years. With these newest
insights, we feel that regular checks every three months for possible chronic Q-fever patients,
as recommended by the Dutch Q-fever Consensus guidelines [16], can be replaced by an
annual follow-up.
The number of studies investigating long-term serological follow-up after Q-fever are
scarce, and recommendations about timing, frequency, and duration of follow-up to rule out
chronic Q-fever are often inconsistent [6]. As far as we know, this is the largest epidemic cohort
with four-year follow-up data ever reported, and it will be difficult to replicate in the absence of
a new larger Q-fever epidemic. Moreover, all patients were diagnosed in one laboratory facility.
In a large epidemic such as the one that occurred in the Netherlands, it is advisable to
actively invite patients for serological follow-up instead of passive follow-up requests, as large
differences have been observed in follow-up rates between both systems [13]. Nevertheless,
Fig 3. Bar charts of IgG phase I (a), IgG phase II (b), IgM phase I (c), and IgM phase II (d) antibody levels
against Coxiella burnetii, four years after acute Q fever episode (n = 1,289). All 47 samples with an IgG
phase I titre1:512 had a negativeC. burnetii PCR result. The numbers presented in the bars indicate the
number of patients.
doi:10.1371/journal.pone.0131848.g003
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Table 4. Risk factors associated with an IgG phase I titre1:512 at four-year follow-up.
Characteristic IgG phase I 1:512 at
four-year follow-up
(index) (n = 47)
IgG phase I <1:512 at four-
year follow-up (reference)
(n = 1,242)
Univariable analysis Multivariable analysisa
n (%) n (%) OR 95% CI p OR 95% CI p
Male gender 28 (59.6) 675 (54.3) 1.24 0.68–2.24 0.481
Age at four-year
follow-up >55 years
32 (68.1) 586 (47.2) 2.39 1.28–4.45 0.005 1.94 1.05–3.76 0.036
Aortic aneurysm 2 (4.3) 4 (0.3) 13.76 2.46–77.07 <0.001 7.47 1.18–47.54 0.033
Vascular prosthesis 2 (4.3) 6 (0.5) 9.16 1.80–46.62 0.001
Heart valve
insufﬁciency /
prosthesisb
4 (8.5) 31 (2.5) 3.63 1.22–10.75 0.020
Myocardial infarction 2 (4.3) 55 (4.4) 0.96 0.23–4.06 0.955
Coronary artery
procedure
Coronary artery
bypass surgery
2 (4.3) 22 (1.8) 2.47 0.56–10.80 0.216
Percutaneous
coronary
intervention
6 (12.8) 46 (3.7) 3.81 1.54–9.41 0.002 2.68 1.00–7.13 0.049
Coronary stent 5 (10.6) 46 (3.7) 3.10 1.17–8.19 0.017
Peripheral arterial
procedurec
2 (4.3) 19 (1.5) 2.86 0.64–12.66 0.147
Pacemaker 2 (4.3) 15 (1.2) 3.64 0.81–16.38 0.072
Rheumatoid arthritis 10 (21.3) 92 (7.4) 3.38 1.63–7.01 0.001 3.10 1.47–6.53 0.003
Crohn’s disease /
ulcerative colitis
0 (0.0) 14 (1.1) NA NA NA
Immunosuppressive
therapyd
Intermediate
suppressive
4 (8.5) 37 (3.0) 3.07 1.05–9.00 0.041
Severe
suppressive
1 (2.1) 13 (1.0) 2.18 0.28–17.08 0.457
Diabetes mellitus
(type 1 and 2)
6 (12.8) 78 (6.3) 2.18 0.90–5.30 0.077
Malignancy 4 (8.5) 75 (6.0) 1.45 0.51–4.14 0.488
Chronic renal
disease
0 (0.0) 18 (1.4) NA NA NA
Asthma 0 (0.0) 41 (3.3) NA NA NA
COPD 2 (4.3) 34 (2.7) 1.58 0.67–6.78 0.535
Organ
transplantation
0 (0.0) 3 (0.2) NA NA NA
Pregnancy in last 5
yearse
1 (2.1) 34 (2.7) 0.77 0.10–5.77 0.801
95% CI: 95% conﬁdence interval; COPD: chronic obstructive pulmonary disease; NA: not applicable; OR: odds ratio.
a Only factors signiﬁcantly (p<0.05) associated in multivariable analysis are presented. Variables included at the start of the multivariable analysis: age
>55 years, aneurysm, vascular prosthesis, heart valve insufﬁciency or prosthesis, percutaneous coronary intervention, pacemaker, peripheral arterial
procedure, rheumatoid arthritis, immunosuppressive therapy, and diabetes mellitus. Area under the curve of ﬁnal model: 0.68 (95%CI: 0.60–0.76).
b Heart valve abnormalities included: having a prosthetic valve, grade 2 valve stenosis or regurgitation, mitral valve prolapse, bicuspid valve or other
congenital cardiopathies, remodelling or thickening of the valve [18, 19]. Reference category is no reported valvular disease or only subtle or minor
abnormalities not meeting our deﬁnition of heart valve disease.
c Peripheral artery bypass, angioplasty or stent.
d Immunosuppressive therapy included cytostatic treatment for cancer, immunosuppressive medication for kidney transplantation, inﬂammatory bowel
disease, rheumatoid arthritis, etc. (e.g. biologicals, high doses of prednisolone (>10 mg/day for >2 weeks) and other corticosteroids). A distinction is made
between intermediate and severe immunosuppression. Intermediate immunosuppressive therapy: oral/rectal administered immunosuppressive drugs;
severe immunosuppressive therapy: subcutaneous/intravenous administered immunosuppressive drugs (including cytostatic treatment) and oral cytostatic
treatment.
e Calculated for women only.
doi:10.1371/journal.pone.0131848.t004
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patients with an asymptomatic C. burnetii infection can also progress to chronic infection [22],
and therefore screening of risk groups (people with heart valve disease, vascular prosthesis or
aneurysm) is useful during an epidemic [6, 23, 24].
For chronic and acute Q-fever, many different case definitions are, or have been used in the
literature [6]. Four years after the acute Q-fever diagnosis, a large number of patients in the
present study still had detectable IgM phase II antibodies, which is considered a marker of
acute infection. This is in contrast to earlier studies that showed undetectable levels within four
months or low levels after eleven months [3, 25]. While presence of IgM phase II is an impor-
tant diagnostic criterion for acute Q-fever in low-endemic areas, such as the Netherlands at the
time of the first outbreak in 2007, its relevance is questionable in late epidemic and endemic sit-
uations because it can also indicate past-resolved Q-fever [26].
The major established risk factors for chronic Q-fever are valvular disease or surgery, vascu-
lar prostheses, and aneurysms [22, 27–29]. Heart valve and vascular endothelium is the pre-
ferred localization of chronic Q-fever. Age has also been reported as a risk factor, and probably
reflects the increased prevalence of cardiovascular diseases and decreased cellular immunity
during aging [10, 22, 30, 31]. We identified age, aneurysm, PCI, and RA as risk factors for an
IgG phase I titre1:512 at four-year follow-up. The use of one cut-off, however, is arbitrary,
and therefore we performed two additional cut-off analyses (1:256 and 1:1,024) and a propor-
tional odds ratio analysis. The risk factors identified in the IgG phase I1:512 analysis were
not confirmed as major risk factor in the additional analyses. This suggests that, besides sero-
logical follow-up for high-risk patients, routine serological follow-up for all other acute Q-fever
patients at twelve months is important.
The individual prescription and use of antibiotics was not recorded for most of the
patients. Previous studies, performed by several authors of the current study, have investi-
gated the role of antibiotic therapy on hospitalization and antibody responses [32, 33]. Both
studies included subjects of the present study. Dijkstra et al. showed that the majority of their
study population, consisting of acute Q-fever patients diagnosed in 2007 or 2008, received
adequate antibiotic treatment (doxycycline, 200 mg/day or moxifloxacin): 60% in 2007,
increasing to 72% in 2008 [32]. Because of increasing awareness among physicians in the con-
secutive years, the number of patients receiving proper antibiotic treatment is expected to be
higher in 2009 than in 2007. This was confirmed by a questionnaire study among general
practitioners performed in 2009, which showed that 95% of the GPs started antibiotic treat-
ment in patients with pneumonia of fever without awaiting the laboratory confirmation [34],
and by a study of Wielders et al. [33]. This latter study investigated the effect of early diagno-
sis and start of treatment on the IgG antibody response in patients diagnosed in 2009. Ade-
quate antibiotic treatment was prescribed in 83% (defined as at least 10 days of doxycycline
(200 mg/day), moxifloxacin (400 mg/day), ciprofloxacin (1,000 mg/day) or cotrimoxazole
(1,920 mg/day)). Early diagnosis and treatment did not prohibit the antibody response up to
one year after the acute Q-fever diagnosis [33].
The initial self-reporting of underlying medical conditions and medication use repre-
sented a limitation of our study. For those participants who reported cardiovascular prob-
lems, we checked the hospital information system to confirm and categorize the conditions.
We were unable to perform this check for all reported underlying diseases, since not all
patients had hospital records and their underlying diseases were only known by their GP.
This difference in quality assessment of medical conditions is a limitation of this study. Fur-
thermore, we do not know if all patients reported all their medical treatments. Another limi-
tation is that a more in-depth analysis of the participants versus non-participants was not
possible, because no detailed data were available except age, sex, geographical location, hospi-
talization for acute Q-fever, and antibody titres. The majority of the patients that did not
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want to participate stated that they were not interested in the study, had no time to partici-
pate, had been too often invited for research, or because of reasons or a disease that is not
related to Q-fever. Nevertheless, the influence of non-participation might have caused some
bias or affected the representativeness.
Conclusions
We recommend a single serological follow-up at twelve months after diagnosis for laboratory-
confirmed acute Q-fever patients without known risk factors for chronic Q-fever (heart valve/
vascular disease or prosthesis), regardless of a compatible clinical presentation during the acute
infection (Fig 4). Further serological and clinical follow-up is required for patients without risk
factors but with IgG phase I1:512 after twelve-month follow-up. We suggest this should be
done on an annual basis until IgG phase I is1:256. Serological and clinical follow-up should
be carried out more frequently, for example every three months, for patients with known risk
factors. For patients with probable or proven chronic Q-fever, we suggest that the guidelines of
the Dutch Q-fever Consensus Group are followed.
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